Cephalon completes Mepha acquisition; GSK to keep Stiefel plant open;

 @FierceBiotech: Researchers see cancer vaccine revolution on the horizon. Story | Follow @FierceBiotech

 @JohnCFierce: Wow. Panel trashes Daxas. I'd put chances of official approval at somewhere between zip and no way. Article | Follow @JohnCFierce

> Cephalon announced that it has today completed its previously announced acquisition of Mepha, the Swiss-based pharmaceutical company. Release

> The Stiefel manufacturing plant purchased by GlaxoSmithKline last year and scheduled for closure in two years, will remain open, saving 211 jobs and adding growth potential at the Oak Hill site along Route 145. Story

> Two more rounds of previously announced layoffs are coming this month at the Pfizer research facility in Chazy. Report

> The newly retired CEO of Roche Pharmaceuticals Bill Burns today led calls for more public-private partnerships in the pharmaceutical industry at the launch of the Italian Institute of Technology's Drug Discovery and Development Unit (D3). Report

> Plans are falling through for a new nonprofit medical research institute that would have created more than 400 jobs in Fairfax County. Item

> The Univ. of Connecticut is just months away from opening a new research building in Farmington to enhance Connecticut's role as a leader in innovative high tech research and technology transfer in the areas of stem cell biology, advanced microscopy and imaging, computational biology and genetics. Report

And Finally... A group of Scientists at Wake Forest University in North Carolina have successfully treated mice with burns using an old inkjet printer.  The technique is called bioprinting and the mice wounds were completely healed within two to three weeks after treatment. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.